Hubei Biocause Pharmaceutical Valuation
Is 627 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 627 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 000627's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 000627's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 627?
Other financial metrics that can be useful for relative valuation.
| What is 627's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥11.76b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -119.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 627's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
601336 New China Life Insurance | 2.3x | 25.3% | CN¥80.2b |
601318 Ping An Insurance (Group) Company of China | 0.8x | 10.5% | CN¥688.7b |
A088350 Hanwha Life Insurance | 0.1x | -93.3% | ₩2.2t |
MTM Momentum Metropolitan Holdings | 0.2x | -13.7% | R27.9b |
000627 Hubei Biocause Pharmaceutical | 0.2x | n/a | CN¥11.8b |
Price-To-Sales vs Peers: 000627 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.9x).
Price to Earnings Ratio vs Industry
How does 627's PE Ratio compare vs other companies in the Asian Insurance Industry?
Price-To-Sales vs Industry: 000627 is good value based on its Price-To-Sales Ratio (0.2x) compared to the Asian Insurance industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is 627's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000627's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.